Description
JC2-11 is an inhibitor of inflammatory corpuscles. JC2-11 inhibits domain-containing protein NLRC 4, absent in melanoma 2 ( AIM 2 ) and non-canonical ( NC ) inflammatory corpuscles. JC2-11 reduces the secretion of caspase-1 ( p20 ), the cleavage of gasdermin D ( GSDMD ), and the releases of IL-1β and lactate dehydrogenases ( LDH ) in inflammatory bodies. JC2-11 inhibits the activation of inflammatory bodies by destroying the production of reactive oxygen species and the activity of caspase-1In VivoJC2-11 (250 µg/mouse; i.p.; single dose) significantly inhibits the release of caspase-1 (p20) and IL-1β in non-canonical (NC) inflammatory bodies, and weakens the activation of NC inflammatory bodies of C57BL/6 mice model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 mice (8 weeks, female). Dosage: 250 µg/mouse. Administration: Intraperitoneal injection; single dose. Result: Exhibited inhibitory effect on NC inflammatory body.Form:SolidIC50& Target:NLRP3 inflammasome